These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 741422)
21. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924 [TBL] [Abstract][Full Text] [Related]
22. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Barnas U; Schmidt A; Haas M; Oberbauer R; Mayer G Nephrol Dial Transplant; 1996 Sep; 11(9):1822-4. PubMed ID: 8918629 [No Abstract] [Full Text] [Related]
23. [Kidney failure, proteinuria, and diabetic nephropathy]. Collart F Rev Med Brux; 2003 Sep; 24(4):A257-62. PubMed ID: 14606290 [TBL] [Abstract][Full Text] [Related]
24. [[Early results of the treatment of diabetes with a (methyl-4-phenylsulfonyl)-1-[perhydrocyclopenta(C)pyrrolyl-2]-3-urea (gliclazide)]. Montenero P; Leotta S Clin Ter; 1978 Aug; 86(4):319-35. PubMed ID: 737962 [No Abstract] [Full Text] [Related]
25. Long term follow-up of the effect of captopril on severe proteinuria in hypertensive diabetic patients. Romero R; Salinas I; Teixidó J; Lucas A; Felip A; Sanmarti A J Hum Hypertens; 1990 Dec; 4(6):671-5. PubMed ID: 2096209 [TBL] [Abstract][Full Text] [Related]
26. Why patients with diabetes, hypertension and/or proteinuria are not on angiotensin converting enzyme inhibitors. Gordian ME; Kelly J Alaska Med; 1998; 40(3):51-4. PubMed ID: 9785612 [No Abstract] [Full Text] [Related]
27. Gastric bypass and resolution of proteinuria in an obese diabetic patient. Izzedine H; Coupaye M; Reach I; Deray G Diabet Med; 2005 Dec; 22(12):1761-2. PubMed ID: 16401325 [TBL] [Abstract][Full Text] [Related]
28. [Risk of chronic renal failure in patients with non-insulin dependent diabetes mellitus with diabetic nephropathy and the stage of permanent proteinuria and arterial hypertension: role of clinical factors]. Dobronravov VA Ter Arkh; 2000; 72(6):52-4. PubMed ID: 10900651 [TBL] [Abstract][Full Text] [Related]
29. [Diabetes mellitus and development of kidney insufficiency]. Pap I; Reinecke U Z Gesamte Inn Med; 1990 Aug; 45(16):485-7. PubMed ID: 2260364 [TBL] [Abstract][Full Text] [Related]
30. Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. Jackson B; Cubela R; Debrevi L; Whitty M; Johnston CI J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S167-9. PubMed ID: 2455124 [TBL] [Abstract][Full Text] [Related]
31. Concomitant macro and microvascular complications in diabetic nephropathy. Alwakeel JS; Al-Suwaida A; Isnani AC; Al-Harbi A; Alam A Saudi J Kidney Dis Transpl; 2009 May; 20(3):402-9. PubMed ID: 19414942 [TBL] [Abstract][Full Text] [Related]
32. [Value of gliclazide in the treatment of early diabetic retinopathy]. Cabral BV; Fernando R; Villegas-Cinco A; Icasas-Cabral E; Cinco L Therapie; 1985; 40(4):231-3. PubMed ID: 4024018 [No Abstract] [Full Text] [Related]
33. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. Pisoni R; Faraone R; Ruggenent P; Remuzzi G J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375 [TBL] [Abstract][Full Text] [Related]
34. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency. Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995 [TBL] [Abstract][Full Text] [Related]
35. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study. Jerums G; Murray RM; Seeman E; Cooper ME; Edgley S; Marwick K; Larkins RG; Martin TJ Diabetes Res Clin Pract; 1987; 3(2):71-80. PubMed ID: 3552537 [TBL] [Abstract][Full Text] [Related]
36. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review]. Pozzi C; Del Vecchio L; Locatelli F G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840 [TBL] [Abstract][Full Text] [Related]
37. Prolonged dietary protein restriction in diabetic nephropathy. Evanoff G; Thompson C; Brown J; Weinman E Arch Intern Med; 1989 May; 149(5):1129-33. PubMed ID: 2719506 [TBL] [Abstract][Full Text] [Related]
38. Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride. Nakamura T; Kawagoe Y; Matsuda T; Ueda Y; Ebihara I; Koide H Diabetes Metab Res Rev; 2005; 21(1):39-43. PubMed ID: 15386824 [TBL] [Abstract][Full Text] [Related]
39. Unusual causes of renal failure in diabetics: two case studies. VenkataRaman TV; Knickerbocker F; Sheldon CV J Okla State Med Assoc; 1990 Apr; 83(4):164-8. PubMed ID: 2191097 [TBL] [Abstract][Full Text] [Related]
40. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM; J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]